Exploring the pharmacotherapeutic options for treating type 2 diabetes

Diabetes Educator

Volumn 34, Issue 3, 2008, Pages

  Kruger, Davida F ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; INCRETIN; PROTEINASE INHIBITOR;

BLOOD; DRUG ANTAGONISM; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; UNITED STATES;

AMYLOID; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PREVALENCE; PROTEASE INHIBITORS; UNITED STATES;

EID: 44349167576     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721708319234     Document Type: Review

References (29)

1. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. National diabetes statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Accessed September 28, 2007.
2. Harris MI Summary. In: Diabetes in America. 2 nd ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services ; 1995. NIH publication 95-1468.
3. American Association of Clinical Endocrinologists Diabetes Medical Guidelines Task Force. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes selfmanagement-2002 update. Endocr Pract. 2002 ; 8 (suppl 1). 40-82.
4. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services ; 2005.
5. Boden G., Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect [review] ? Diabetes Care. 2004 ; 27: 2253-2259.
6. Ramlo-Halsted BA, Edelman SV The natural history of type 2 diabetes: implications for clinical practice. Diabetes. 1999 ; 26: 771-789.
7. Müller WA, Faloona GR, Aguilar-Parada E., Unger RH Abnormal alpha-cell function in diabetes. N Engl J Med. 1970 ; 283: 109-115.
8. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007 ; 30 (suppl 1). S4 - S41.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329: 977-986.
10. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Prac. 1995 ; 28: 103-117.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853.
12. Stratton IM, Adler AI, Neil HAW, et al, for the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 ; 321: 405-412.
13. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003 ; 26: 881-885.
14. Hanefeld M., Bouter KP, Dickinson S., Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000 ; 23: 202-207.
15. Wolffenbuttel BHR, Landgraf R., for the Dutch and German Repaglinide Study Group. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care. 1999 ; 22: 463-467.
16. Precose [package insert]. West Haven, CT: Bayer Pharmaceuticals Corporation ; 2004.
17. Lebovitz HE, Dole JF, Patwardhan R., Rappaport EB, Freed MI, for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001 ; 86: 280-288.
18. Aronoff S., Rosenblatt S., Braithwaite S., Egan JW, Mathisen AL, Schneider RL, for the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care. 2000 ; 23: 1605-1611.
19. Goldberg RB, Holvey SM, Schneider J., for the Glimeperide Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996 ; 19: 849-856.
20. Simonson DC, Kourides IA, Feinglos M., Shamoon H., Fischette CT, for the Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care. 1997 ; 20: 597-606.
21. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997 ; 102: 491-497.
22. Feinglos M., Dailey G., Cefalu W., et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract. 2005 ; 68: 167-175.
23. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995 ; 44: 1249-1258.
24. Turner RC, Cull CA, Frighi V., Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999 ; 281: 2005-2012.
25. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc ; 2005.
26. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc ; 2007.
27. Januvia [packet insert]. Whitehouse Station, NJ: Merck & Co, Inc ; 2006.
28. Kieffer TJ, Habener JF The glucagon-like peptides. Endocr Rev. 1999 ; 20: 876-913.
29. Deacon CF Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004 ; 53: 2181-2189.